Diabetes and metabolic dysfunction-associated fatty liver disease

Area of Science:

• Hepatology
• Endocrinology
• Metabolic Diseases

Background:

• Metabolic dysfunction-associated fatty liver disease (MAFLD) is a novel classification shifting focus from alcohol to metabolic risk factors.
• MAFLD diagnosis includes individuals with type 2 diabetes (T2D) and hepatic fat content exceeding 5%.

Purpose of the Study:

• To review contemporary methods for quantifying liver fat and fibrosis in T2D patients with MAFLD.
• To assess prognostic implications and factors influencing MAFLD progression in T2D.
• To discuss emerging therapies for MAFLD with potential impact on T2D outcomes.

Main Methods:

• Review of current literature on MAFLD diagnosis and management in T2D.
• Focus on magnetic resonance imaging (MRI) and other biomarkers for liver fat and fibrosis quantification.
• Analysis of epidemiological trends and therapeutic advancements.

Main Results:

• Limited studies exist on MAFLD specifically within the T2D population.
• Accurate quantification of liver fat and fibrosis is crucial for assessing MAFLD prognosis in T2D.
• Obesity and cardiovascular disease epidemiology are intertwined with MAFLD progression.

Conclusions:

• MAFLD represents a significant challenge in T2D management.
• Improved diagnostic tools and targeted therapies are needed for better MAFLD outcomes in T2D.
• Future research should focus on novel interventions for MAFLD in the context of metabolic syndrome.